Bionano Genomics, Inc.【BNGO】

時価総額

$373.4万

PER

ゲノム解析ソリューションの新興企業。光学ゲノムマッピング（OGM）機器、VIA解析ソフト、Ionic精製システムを展開。分析ソフト買収で約5,230万ドルの現金支払い、DNA抽出企業買収で約3,200万ドルの現金支払い。米国中心に展開。

	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-18,496,392	-29,815,070	-41,106,351	-72	-133	-232	-112
Depreciation and amortization expense	1	1	1	3	10	14	14
Goodwill impairment	-	-	-	-	-	77	-
Inventory write-offs	1	-	125,640	-	-	-	7
Finance Lease, Right-of-Use Asset, Amortization	-	-	-	0	0	0	0
Accretion of interest on securities	-	-	-	-	-	1	1
Net realized loss on investments	-	-	-	-	-0	-0	-0
Non-cash lease expense	-	-	-	1	0	0	-0
Gain on lease modification	-	-	-	-	-	-	0
Stock-based compensation	1	1	2	10	22	15	10
Cost of leased equipment sold to customer	-	-	-	1	0	0	0
Change in fair value of contingent consideration	-	-	-	0	0	-1	-11
Fair Value, Option Liability and Notes Payable, Changes in Fair Value, Gain (Loss)	-	-	-	-	-	-1	-8
Loss on issuance of convertible debentures	-	-	-	-	-	-	-2
Gain on High Trail extinguishment	-342,164	-1,333,496	-	-2	-	-	4
Loss on extinguishment of convertible debentures payable	-	-	-	-	-	-	-7
Disposal of internal-use software	-	-	-	-	-	-	1
Intangible assets and other long-lived assets impairment	-	-	-	-	-	-	18
Long-lived assets held for sale impairment	-	-	-	-	-	-	0
Right-of-use-asset impairment	-	-	-	-	-	-	1
Disposal of property and equipment	-	-	-	-	-	-	-1
Accounts receivable	900,119	2	-2,086,927	0	3	2	-4
Inventory	418,984	4	4	16	24	4	1
Prepaid expenses and other current assets	-152,012	245,046	999,194	2	3	-1	-2
Other assets	-	-	-	-	1	5	-5
Accounts payable	-954,377	1	-1,809,309	7	2	-2	-3
Accrued expenses and contract liabilities	-247,402	-73,910	1	4	0	-3	-2
Net cash used in operating activities	-19,943,847	-29	-38,314,378	-72	-125	-125	-69
Purigen acquisition, return of purchase consideration from escrow	-	-	-	-	-	0	-
Purchases of property and equipment	-	-	-	-	-	2	0
Purchase of available for sale securities	-	-	-	313	84	111	233
Sale and maturities of available for sale securities	-	-	-	-	201	137	307
Net cash provided by investing activities	-331,716	-61,056	-2,449,952	-278	83	24	74
Principal payments of financing lease liability	-	-	-	0	0	0	0
Proceeds from Issuance of Common Stock	-	-	-	-	-	58	44
Offering expenses on sale of common stock and warrants	-	-	2	2	1	1	3
Proceeds from Stock Plans	-	-	-	-	-	-	0
Proceeds from warrant and option exercises	-	-	-	-	-	-	0
Proceeds from Convertible Debt	14	5	760,527	-	-	-	18
Payments on High Trail notes	-	-	-	-	-	-	61
Payments on convertible debentures	-	-	-	-	-	9	5
Debt issuance costs on sale of convertible debentures	-	-	-	-	-	5	2
Payments of retirement fees for redemption of High Trail notes	-	-	-	-	-	-	5
Contingent consideration milestone payment	-	-	-	-	-	9	-
Net cash provided by (used in) financing activities	36	30	62	336	23	114	-14
Effect of exchange rates on cash and cash equivalents and restricted cash	-	-	-	-	-0	0	-0
Net increase (decrease) in cash and cash equivalents and restricted cash	16	788,644	21	-14	-19	13	-9
Cash paid for interest	700,353	1	1	2	0	2	11
Operating Lease, Payments	-	-	-	0	2	3	3
Transfer Of Instruments And Servers	-	-	-	-	-	-	5
Capital Expenditures Incurred but Not yet Paid	3,150	-	-	-	0	0	-
Debt Issuance Costs Incurred but Not yet Paid	-	-	-	-	-	0	-
Conversion Of Notes Payable Into Common Stock, Fair Value	-	-	-	-	-	7	-
Accrued liability for fees to be paid in common stock	-	-	-	-	-	-	2
Non-cash Fill-Up Amount	-	-	-	-	-	-	0